Logo

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab to Treat Esophageal Squamous Cell Carcinoma in China

Share this

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab to Treat Esophageal Squamous Cell Carcinoma in China

Shots:

  • The sBLA is based on P-III RATIONALE 302 trial evaluating efficacy & safety of tislelizumab vs CT as a 2L treatment in 512 patients in a ratio (1:1) with locally advanced or metastatic ESCC across 11 countries
  • The 1EPs of a trial is OS in ITT populations & 2EPs is OS in patients with high PD-L1 expression including PFS- ORR- DoR- & safety
  • Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 mAb- designed to minimize binding to FcγR on macrophages. In Jan’21- BeiGene & Novartis have entered into a license agreement in which Novartis gets the rights to develop- manufacture & commercialize tislelizumab in North America- EU & Japan

  Ref: Businesswire | Image: Yicai Global

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions